Mr. Ratcliffe is Partner of Sands Capital Ventures and joined in January 2016. He is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture and private equity investor. Mr. Ratcliffe has served in many roles as a founder, CEO, CFO, COO, chairman, director and advisor to a number of privately-held Life Science product and service businesses. He has focused on the cell signaling, drug screening, genomics and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sale. Prior to joining Sands Capital, Mr. Ratcliffe was the Chairman and CEO of Enzymatics Inc. (Boston) until the sale of the company to Qiagen (NASDAQ:QGEN) in December 2014. Mr. Ratcliffe is also Chairman and a director of AsterandBio Inc. (Detroit and Cambridge, UK), a leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. He was the founder and CEO of Stemgent Inc., a stem and iPS cell life science tools company sold to ReproCELL Inc (on JP:TYO) in 2014. Mr. Ratcliffe was a founding investor in Firefly Bioworks, sold to Abcam (LSE:ABCA) in 2014 and Genometry Inc., a spin-out from the Broad Inst. the world leader in efficient gene expression profiling. He is a director of Quad Technologies (Boston), a biotech company commercializing proprietary cell separation technology. In his previous career, he served as President of Upstate, Inc. a leading provider of cell signaling research products and services. In this position Mr. Ratcliffe was instrumental in facilitating the acquisition of Upstate by Serologicals, Corp. and was subsequently retained as President of the Upstate division. Mr. Ratcliffe has a degree in Chemical Engineering from University of Surrey and has an MBA from the Darden School at the University of Virginia, where he received a William Shermet Award and a Faculty Award for Academic Excellence.
G. Houston Hall
Mr. Hall is a co-founder and manager of Falcon Fund, a long-short equity hedge fund founded in 1990. Mr. Hall is also a co-founder of BioMatrix Partners, an investment partnership focused on public and private biotechnology companies, with an emphasis on early-stage opportunities enabled by synthetic biology. Mr. Hall has invested in a wide range of businesses for over 25 years.
Alexander M. Seaver
Mr. Seaver is a co-founder and Managing Director of Stadium Capital Management, LLC, as well as a co-founder of Coliseum Capital Management, LLC. Stadium Capital Management, LLC, founded in 1999, and Coliseum Capital Management, LLC, founded in 2006, currently manage more than $1.7 billion combined. Mr. Seaver is also a co-founder of Gold Bench Capital. He has deep experience in venture capital, private equity and public market investing.
Adrian Z. Stecyk
Mr. Stecyk is a co-Founder of Griffin Agilis, LLC, and Griffin Securities, Inc. He is also Chief Executive Officer of Griffin Securities, Inc. with over 20 years of investment industry experience. At Griffin, Mr. Stecyk focuses on the firm’s investment banking and advisory activities, working with many new and emerging companies in healthcare, technology and other disruptive categories, both public and private. Prior to entering the financial services industry, Adrian Stecyk served as an engineer with Charles Stark Draper Laboratory, a technology R&D company focused on design, development and deployment of advanced technological solutions for some of the nation’s most challenging problems in security, space, healthcare, energy and technology. Mr. Stecyk has a B.S. in Aerospace Engineering and an M.B.A. in Finance from Boston University.
Mark J. Pykett, VMD PhD President and Chief Executive Officer
Dr. Pykett is the President and Chief Executive Officer of Agilis Biotherapeutics, and he has two decades of experience in the pharmaceutical industry. Previously he served as Chief Executive Officer of Navidea Biopharmaceuticals, a precision medicine company focused on oncology and neurology. Prior to Navidea, Dr. Pykett was President and Chief Operating Officer of Alseres Pharmaceuticals, a biotechnology company focused on neurodegenerative and central nervous system disorders. Before Alseres, Dr. Pykett held senior executive roles at several public and private companies, including CEO of Cytomatrix and President of Cygenics, focused on a range of therapeutic areas, indications and products. Dr. Pykett has also served as a Director of several public and private companies, and of the not-for-profit organization HealthBuilders, developing health infrastructure in central Africa. Dr. Pykett received a B.A. degree from Amherst College, a V.M.D. and Ph.D. from the University of Pennsylvania, and an M.B.A. from Northeastern University, and completed post-doctoral fellowships at the University of Pennsylvania and Harvard University.